Armis Named a Leader in 2025 Gartner® Magic Quadrant™ for CPS Protection Platforms
18.2.2025 17:30:00 CET | Business Wire | Press release
Armis supports global enterprises’ vast and varied needs to effectively secure critical CPS environments
Armis, the cyber exposure management & security company, today announced that it has been named a Leader in the 2025 Gartner Magic Quadrant for CPS Protection Platforms.
Cyber-physical system environments connect the physical and digital worlds, supporting sectors including infrastructure, transportation, healthcare and smart manufacturing. Their growing role increases risk due to complex IT, OT, IoT, and IIoT integrations that need robust security. We believe the Gartner Magic Quadrant for CPS Protection Platforms highlights the importance of protecting these systems.
“Attacks on cyber-physical systems can disrupt operations and endanger lives, making their security our core mission, driven by innovation, expertise and customer collaboration,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “We believe being named a Leader in this report is a testament to the support that we provide and the partnerships that we have with our customers as part of our unwavering commitment to redefining and advancing the security of cyber-physical systems. We will continue to innovate to protect society as we know it from the attacks of cybercriminals and nation-state adversaries who aim to cause disruption and harm.”
Armis was named a Leader within this report among the 17 vendors that were evaluated. Armis Centrix™, the Armis Cyber Exposure Management Platform, was positioned within the report for its Completeness of Vision and Ability to Execute.
As of February 11, 2025, Armis had 28 reviews on Gartner Peer Insights™ in the CPS Protection Platform category with an overall rating of 4.7 out of 5. Read customers’ praises of Armis’ CPS Protection Platform solution through verified ratings and reviews on Gartner® Peer Insights here and below:
- “Support for this product is by far the best I've encountered out of any product I use here. The usefulness of this product is pivotal for visibility of devices on our network.” - Manager, IT Security and Risk Management (Industry: Manufacturing)
- “Armis provides the Cybersecurity team with what it needs seamlessly. It helps us manage our assets, identify and resolve vulnerabilities faster, and helps us make better decisions on our security policy. Our customer success manager has always made himself available to us, which is key in being able to understand Armis' capabilities and how it benefits our organization.” - Cybersecurity Administrator (Industry: Government)
- “The company does a phenomenal job at listening to our questions/concerns and implementing a solution. They are truly customer focused.” - IT Security & Risk Management Associate (Industry: Healthcare and Biotech)
- "We had a positive experience with the vendor. Their team was consistently professional, prepared, and responsive. They also had initiatives for different use cases that were off our list initially. They demonstrated a strong understanding of the solution and the industry. Overall, the service was reliable and met our expectations well.” - Manager, IT Security (Industry: Retail)
- “Great experience. We have added a ton of visibility in our environment.” - IT Security & Risk Management Associate (Industry: Healthcare and BioTech)
Read our blog to learn more about why Armis was named a Leader in the 2025 Gartner® Magic Quadrant for CPS Protection Platforms.
Find more information about Armis Centrix™, the cyber exposure management platform, here.
For additional analyst reports recognizing Armis, please visit our Analyst Relations webpage.
Gartner Disclaimer
Gartner, Magic Quadrant for CPS Protection Platforms, Katell Thielemann, Wam Voster, Ruggero Contu, 12 February 2025.
Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT and PEER INSIGHTS is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
About Armis
Armis, the cyber exposure management & security company, protects the entire attack surface and manages the organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets – from the ground to the cloud. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218934891/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements15.6.2026 12:00:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Global Market's listing requirements. As noted in the Hearing Panel's May 20, 2026 compliance determination, the Company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027. The Company filed its annual report on Form 20-F for the year ended December 31, 2025 on June 5, 2026. The Notification Letter also stated that the hearing before the Hearings Panel, applied for by the Company, had accordingly been canceled. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission
KRM22 partners with Sigma AI to enhance market surveillance and risk intelligence capabilities15.6.2026 12:00:00 CEST | Press release
KRM22, the technology and software investment company focused on risk management solutions for capital markets, today announced a strategic partnership with Sigma AI, a leading provider of AI-driven financial insights, to integrate advanced news sentiment analytics into its risk management application suite. The integration marks a significant enhancement to KRM22’s capabilities, enabling clients to incorporate real-time market sentiment insights derived from global news sources directly into their risk frameworks. By leveraging Sigma AI’s proprietary natural language processing and machine learning models, KRM22 will help firms better identify emerging risks, anticipate market-moving events, and make more informed trading and compliance decisions. Advancing risk management through AI-driven sentiment analysis As part of the first phase of the collaboration, KRM22 will embed Sigma AI’s news sentiment engine within its application suite. This will provide users with actionable intellige
HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 11:15:00 CEST | Press release
The first SaaS SuperApp for startups and VCs capitalizes on a $25M round a from Nimbus Capital and a +15% stock surge, unveiling a v3/v4 roadmap that bridges public equity with digital asset liquidity. HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026061293689
Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release
Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom